

# Wolf H Fridman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033082/publications.pdf>

Version: 2024-02-01

44  
papers

19,348  
citations

101496

36  
h-index

254106

43  
g-index

48  
all docs

48  
docs citations

48  
times ranked

22533  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, 501-511.	1.9	14
2	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. <i>Immunity</i> , 2022, 55, 527-541.e5.	6.6	215
3	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 441-457.	12.5	176
4	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
5	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. , 2022, 10, e004885.		13
6	Les structures lymphoïdes tertiaires g�nent et propagent des plasmocytes produisant des anticorps antitumoraux dans le cancer du rein. <i>Medecine/Sciences</i> , 2022, 38, 536-538.	0.0	0
7	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. <i>Methods in Molecular Biology</i> , 2021, 2227, 191-203.	0.4	5
8	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021, 9, 891-908.	1.6	43
9	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 240.	3.5	3
10	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	5.7	173
11	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	91
12	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020, 158, 303-321.	0.6	51
13	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020, 12, 86.	3.6	63
14	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020, 48, 101406.	2.7	44
15	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020, 9, 57.	1.2	58
16	Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. <i>Frontiers in Immunology</i> , 2020, 11, 951.	2.2	221
17	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339
18	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	13.7	1,158

#	ARTICLE	IF	CITATIONS
19	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
20	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , 2020, 26, 4381-4389.	3.2	44
21	Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. <i>Bioinformatics</i> , 2019, 35, i436-i445.	1.8	576
22	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 698-715.	12.8	217
23	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019, 7, 1091-1105.	1.6	153
24	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879
25	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	3.2	61
26	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 58-65.	1.8	219
27	Association of IL-36 $\beta$ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 109-120.	2.0	59
28	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 981-988.	2.0	89
29	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
30	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2018, 8, 390.	1.3	46
31	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	3.2	252
32	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
33	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2016, 7, 407.	2.2	238
34	Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. <i>Immunological Reviews</i> , 2016, 271, 260-275.	2.8	277
35	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016, 17, 218.	3.8	1,980
36	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 4057-4066.	3.2	433

#	ARTICLE	IF	CITATIONS
37	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
38	TLS in Tumors: What Lies Within. <i>Trends in Immunology</i> , 2016, 37, 1-2.	2.9	24
39	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>Oncoimmunology</i> , 2015, 4, e1049804.	2.1	51
40	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3031-3040.	3.2	355
41	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	1.4	51
42	Tertiary lymphoid structures in cancer and beyond. <i>Trends in Immunology</i> , 2014, 35, 571-580.	2.9	418
43	Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer. <i>Immunity</i> , 2013, 39, 782-795.	6.6	2,983
44	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 298-306.	12.8	3,873